Manuela Pennisi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manuela Pennisi has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Lanza
Department of Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy
64 shared publications - Mariagiovanna Cantone
Unit of Neurology, Policlinico University Hospital “G. Rodolico-San Marco”, 95123 Catania, Italy
46 shared publications - Rita Bella
Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, University of Catania, 95123 Catania, Italy
42 shared publications - Raffaele Ferri
Oasi Research Institute-IRCCS, 94018 Troina, Italy
32 shared publications Rita Bella
Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, Catania, Italy
24 shared publications- Francesco Fisicaro
Primary Health Care Unit, Provincial Health Authority of Siracusa, 96100 Siracusa, Italy
21 shared publications
Latest Publications
- Open Access
Update on Repetitive Transcranial Magnetic Stimulation in Post-Stroke Cognitive Rehabilitation: A Systematic Review of Randomized Clinical Trials
Background: We synthesized evidence from randomized clinical trials (RCTs) published between 2019 and 2025 on repetitive transcranial magnetic stimulation (rTMS) in post-stroke cognitive impairment (PSCI) and compared different stimulation parameters, cortical targets, and combinations with rehabilitation interventions. Methods: A systematic review according to PRISMA guidelines examined the RCTs applying rTMS in adults with PSCI compared with control or sham groups. The primary outcome was improvement in cognitive function and functional outcomes measured with standardized scales. Results: Fifteen studies, involving a total of 732 patients, were included. The most frequently investigated were high-frequency (≥10 Hz) stimulation protocols of the left dorsolateral prefrontal cortex, with treatment cycles ranging from 2 to 6 weeks. Overall, rTMS was generally safe and well tolerated, with rare and mild adverse events. Several studies reported improvements in cognitive performance following rTMS, although effects were variable across trials and need caution in light of heterogeneity in stimulation protocols, sample sizes, outcome measures, and methodological quality. In most cases, rTMS or intermittent theta burst stimulation combined with structured cognitive training yielded greater cognitive and functional gains than stimulation or rehabilitation alone. This suggests a positive interaction between rTMS and cognitive training, although current evidence does not yet allow definitive conclusions. Conclusions: rTMS appears to be a promising strategy for post-stroke cognitive rehabilitation, particularly for attention and executive functioning. However, heterogeneity in stimulation protocols and outcome measures, along with limited sample sizes and short follow-up, reduces the certainty and comparability of current evidence. The widespread reliance on global screening tools may further underestimate domain-specific effects. Future multicentre trials with standardized protocols and more sensitive cognitive assessments are needed to clarify efficacy and guide further clinical application of rTMS in PSCI.
Open AccessUpdate on Repetitive Transcranial Magnetic Stimulation in Post-Stroke Cognitive Rehabilitation: A Systematic Review of Randomized Clinical Trials
Background: We synthesized evidence from randomized clinical trials (RCTs) published between 2019 and 2025 on repetitive transcranial magnetic stimulation (rTMS) in post-stroke cognitive impairment (PSCI) and compared different stimulation parameters, cortical targets, and combinations with rehabilitation interventions. Methods: A systematic review according to PRISMA guidelines examined the RCTs applying rTMS in adults with PSCI compared with control or sham groups. The primary outcome was improvement in cognitive function and functional outcomes measured with standardized scales. Results: Fifteen studies, involving a total of 732 patients, were included. The most frequently investigated were high-frequency (≥10 Hz) stimulation protocols of the left dorsolateral prefrontal cortex, with treatment cycles ranging from 2 to 6 weeks. Overall, rTMS was generally safe and well tolerated, with rare and mild adverse events. Several studies reported improvements in cognitive performance following rTMS, although effects were variable across trials and need caution in light of heterogeneity in stimulation protocols, sample sizes, outcome measures, and methodological quality. In most cases, rTMS or intermittent theta burst stimulation combined with structured cognitive training yielded greater cognitive and functional gains than stimulation or rehabilitation alone. This suggests a positive interaction between rTMS and cognitive training, although current evidence does not yet allow definitive conclusions. Conclusions: rTMS appears to be a promising strategy for post-stroke cognitive rehabilitation, particularly for attention and executive functioning. However, heterogeneity in stimulation protocols and outcome measures, along with limited sample sizes and short follow-up, reduces the certainty and comparability of current evidence. The widespread reliance on global screening tools may further underestimate domain-specific effects. Future multicentre trials with standardized protocols and more sensitive cognitive assessments are needed to clarify efficacy and guide further clinical application of rTMS in PSCI.
- 7 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1)
Dream-enactment behaviors without REM sleep without atonia
To compare clinical and polysomnographic features of patients with isolated REM sleep behavior disorder (iRBD) and patients with clinically reported dream-enactment behaviors (DEB) occurring in the absence of REM sleep without atonia (RSWA), and to clarify the clinical significance of DEB without RSWA. We retrospectively reviewed clinical records and polysomnography of consecutive patients referred to a tertiary sleep and neurology center. Twenty-six patients with polysomnography-confirmed iRBD, 21 patients with DEB without RSWA, and 24 control subjects were included. Clinical features related to prodromal neurodegeneration, neuroimaging findings, sleep architecture, REM atonia indices, limb movements, and respiratory parameters were analyzed using age-adjusted comparisons with effect size estimation. Compared with DEB patients, iRBD patients were older and showed a higher prevalence of subtle extrapyramidal signs, lower cognitive performance, and a greater burden of vascular neuroimaging abnormalities. Clinically reported hyposmia and depression were infrequent and did not differ between groups. Both clinical groups exhibited increased sleep fragmentation and instability, most pronounced in iRBD, with DEB patients showing intermediate values. REM atonia robustly differentiated groups, whereas periodic limb movements during sleep and respiratory disturbance did not differ significantly after age adjustment. DEB occurring without RSWA are associated with a clinical and polysomnographic profile distinct from iRBD, characterized by preserved REM atonia and a lower burden of markers linked to prodromal neurodegeneration. These findings highlight the heterogeneity of DEB and support characterization beyond conventional RBD diagnostic criteria. Current knowledge/study rationale: Isolated REM sleep behavior disorder (iRBD) is defined by dream-enactment behaviors (DEB) with REM sleep without atonia (RSWA), whereas clinically reported DEB without RSWA presents a diagnostic challenge and unclear significance in relation to prodromal neurodegeneration. Study impact: In this retrospective tertiary-center cohort, iRBD patients had more extrapyramidal signs, lower cognitive performance, and greater vascular imaging abnormalities compared with DEB without RSWA, whereas both groups showed increased sleep instability. These findings highlight that DEB without RSWA has a distinct clinical and polysomnographic profile, supporting the need for characterization beyond conventional RBD diagnostic criteria.
- 7 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1)
Dream-enactment behaviors without REM sleep without atonia
To compare clinical and polysomnographic features of patients with isolated REM sleep behavior disorder (iRBD) and patients with clinically reported dream-enactment behaviors (DEB) occurring in the absence of REM sleep without atonia (RSWA), and to clarify the clinical significance of DEB without RSWA. We retrospectively reviewed clinical records and polysomnography of consecutive patients referred to a tertiary sleep and neurology center. Twenty-six patients with polysomnography-confirmed iRBD, 21 patients with DEB without RSWA, and 24 control subjects were included. Clinical features related to prodromal neurodegeneration, neuroimaging findings, sleep architecture, REM atonia indices, limb movements, and respiratory parameters were analyzed using age-adjusted comparisons with effect size estimation. Compared with DEB patients, iRBD patients were older and showed a higher prevalence of subtle extrapyramidal signs, lower cognitive performance, and a greater burden of vascular neuroimaging abnormalities. Clinically reported hyposmia and depression were infrequent and did not differ between groups. Both clinical groups exhibited increased sleep fragmentation and instability, most pronounced in iRBD, with DEB patients showing intermediate values. REM atonia robustly differentiated groups, whereas periodic limb movements during sleep and respiratory disturbance did not differ significantly after age adjustment. DEB occurring without RSWA are associated with a clinical and polysomnographic profile distinct from iRBD, characterized by preserved REM atonia and a lower burden of markers linked to prodromal neurodegeneration. These findings highlight the heterogeneity of DEB and support characterization beyond conventional RBD diagnostic criteria. Current knowledge/study rationale: Isolated REM sleep behavior disorder (iRBD) is defined by dream-enactment behaviors (DEB) with REM sleep without atonia (RSWA), whereas clinically reported DEB without RSWA presents a diagnostic challenge and unclear significance in relation to prodromal neurodegeneration. Study impact: In this retrospective tertiary-center cohort, iRBD patients had more extrapyramidal signs, lower cognitive performance, and greater vascular imaging abnormalities compared with DEB without RSWA, whereas both groups showed increased sleep instability. These findings highlight that DEB without RSWA has a distinct clinical and polysomnographic profile, supporting the need for characterization beyond conventional RBD diagnostic criteria.
- Open Access
- 4 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1932
Repetitive Transcranial Magnetic Stimulation for Spasticity in Stroke and Other Neuromotor Disorders: A Systematic Review of Randomized Clinical Trials
Background: Spasticity is a common and disabling feature of several neuromotor disorders. Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a non-invasive approach to modulate corticospinal excitability and reduce spasticity, although its clinical effectiveness remains debated. This systematic review evaluated the efficacy and safety of rTMS in reducing spasticity in stroke and other neuromotor conditions. Methods: A systematic search of PubMed, Scopus, and Cochrane Library was conducted up to June 2025 in accordance with PRISMA 2020 guidelines. Eligible studies were randomized controlled trials (RCTs) comparing rTMS with sham stimulation or conventional therapy and assessing spasticity using validated scales, primarily the Modified Ashworth Scale. Included populations comprised patients with stroke, spinal cord injury, multiple sclerosis, cerebral palsy, and hereditary spastic paraplegia. Risk of bias was assessed using the RoB 2.0 tool, and certainty of evidence was evaluated with GRADE. Results: Twenty-six RCTs were included, mainly involving stroke patients. Most studies reported a significant reduction in spasticity with rTMS compared with control interventions. Low-frequency stimulation was commonly used after stroke, while excitatory protocols predominated in other conditions. Benefits generally persisted for up to 12 weeks. Evidence quality was moderate, and no serious adverse events were reported. Conclusions: rTMS appears to be a safe and promising adjunctive treatment for spasticity across neuromotor disorders. However, protocol heterogeneity and small sample sizes limit definitive clinical recommendations, highlighting the need for standardized, larger-scale studies.
- 4 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1932
Open AccessRepetitive Transcranial Magnetic Stimulation for Spasticity in Stroke and Other Neuromotor Disorders: A Systematic Review of Randomized Clinical Trials
Background: Spasticity is a common and disabling feature of several neuromotor disorders. Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a non-invasive approach to modulate corticospinal excitability and reduce spasticity, although its clinical effectiveness remains debated. This systematic review evaluated the efficacy and safety of rTMS in reducing spasticity in stroke and other neuromotor conditions. Methods: A systematic search of PubMed, Scopus, and Cochrane Library was conducted up to June 2025 in accordance with PRISMA 2020 guidelines. Eligible studies were randomized controlled trials (RCTs) comparing rTMS with sham stimulation or conventional therapy and assessing spasticity using validated scales, primarily the Modified Ashworth Scale. Included populations comprised patients with stroke, spinal cord injury, multiple sclerosis, cerebral palsy, and hereditary spastic paraplegia. Risk of bias was assessed using the RoB 2.0 tool, and certainty of evidence was evaluated with GRADE. Results: Twenty-six RCTs were included, mainly involving stroke patients. Most studies reported a significant reduction in spasticity with rTMS compared with control interventions. Low-frequency stimulation was commonly used after stroke, while excitatory protocols predominated in other conditions. Benefits generally persisted for up to 12 weeks. Evidence quality was moderate, and no serious adverse events were reported. Conclusions: rTMS appears to be a safe and promising adjunctive treatment for spasticity across neuromotor disorders. However, protocol heterogeneity and small sample sizes limit definitive clinical recommendations, highlighting the need for standardized, larger-scale studies.
- Open Access
Transcranial Magnetic Stimulation in Parkinson’s Disease and Parkinsonian Syndromes: A Narrative Expert Review
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation tool for investigating the neurophysiology of different neurological and neuropsychiatric disorders, including Parkinson’s disease (PD) and other parkinsonian syndromes and movement disorders. Briefly, TMS enables targeted stimulation of specific cortical regions through externally applied magnetic pulses, avoiding surgical intervention (as it occurs in deep brain stimulation) and making it a safe, repeatable, and well-tolerated approach. Over the past two decades, extensive research has explored the clinical utility of TMS in PD, with particular emphasis on motor cortex excitability, synaptic plasticity, and functional connectivity, which are central contributors to both motor and non-motor symptoms in PD patients. In addition, repetitive TMS and related stimulation paradigms have been shown to positively modulate cortical plasticity, i.e., the brain’s capacity to reorganize neural circuits, suggesting potential benefits for longer-term non-pharmacological management and rehabilitation protocols. More recently, studies have also investigated the role of TMS in atypical and secondary parkinsonisms, indicating that it may help characterize distinct neurophysiological abnormalities and provide symptomatic improvement in selected patients. This narrative expert review provides a comprehensive summary of TMS applications across the wide spectrum of parkinsonian syndromes, highlighting not only clinical potential, but also methodological limitations and future research directions.
Open AccessTranscranial Magnetic Stimulation in Parkinson’s Disease and Parkinsonian Syndromes: A Narrative Expert Review
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation tool for investigating the neurophysiology of different neurological and neuropsychiatric disorders, including Parkinson’s disease (PD) and other parkinsonian syndromes and movement disorders. Briefly, TMS enables targeted stimulation of specific cortical regions through externally applied magnetic pulses, avoiding surgical intervention (as it occurs in deep brain stimulation) and making it a safe, repeatable, and well-tolerated approach. Over the past two decades, extensive research has explored the clinical utility of TMS in PD, with particular emphasis on motor cortex excitability, synaptic plasticity, and functional connectivity, which are central contributors to both motor and non-motor symptoms in PD patients. In addition, repetitive TMS and related stimulation paradigms have been shown to positively modulate cortical plasticity, i.e., the brain’s capacity to reorganize neural circuits, suggesting potential benefits for longer-term non-pharmacological management and rehabilitation protocols. More recently, studies have also investigated the role of TMS in atypical and secondary parkinsonisms, indicating that it may help characterize distinct neurophysiological abnormalities and provide symptomatic improvement in selected patients. This narrative expert review provides a comprehensive summary of TMS applications across the wide spectrum of parkinsonian syndromes, highlighting not only clinical potential, but also methodological limitations and future research directions.
- Open Access
Anxiety-Related Functional Dizziness: A Systematic Review of the Recent Evidence on Vestibular, Cognitive Behavioral, and Integrative Therapies
Background: Functional dizziness and persistent postural-perceptual dizziness (PPPD) involve mutually reinforcing vestibular symptoms and anxiety. Non-pharmacological interventions, such as vestibular rehabilitation therapy (VRT) and cognitive behavioral therapy (CBT), aim to address both mechanisms, yet their overall effectiveness remains unclear. Methods: We systematically examined randomized controlled trials (RCTs) published between 2000 and 2025 that evaluated VRT, CBT, or multimodal approaches for adults with functional or chronic dizziness (including PPPD and related functional dizziness constructs) accompanied by significant anxiety. Twelve RCTs (513 participants) met the criteria, involving individuals with PPPD, chronic subjective dizziness, chronic vestibular disorders with prominent anxiety, and residual dizziness after benign paroxysmal positional vertigo. Results: Conventional VRT delivered in clinic or as structured home-based programs produced small-to-moderate improvements in dizziness-related disability versus usual care. Combining VRT with CBT or psychologically informed components yielded larger and more consistent reductions in disability and maladaptive dizziness-related beliefs. CBT-based interventions reduced anxiety and dizziness-related distress compared with supportive controls. Emerging modalities, including virtual-reality-based VRT, non-invasive neuromodulation, and heart-rate-variability biofeedback, showed potential, although they were limited by small samples and methodological issues. Most trials had some risk-of-bias concerns and evidence certainty ranged from very low to moderate. Conclusions: Integrated multimodal rehabilitation shows promise, although larger, high-quality RCTs using standardized procedures and outcome measures are required.
Open AccessAnxiety-Related Functional Dizziness: A Systematic Review of the Recent Evidence on Vestibular, Cognitive Behavioral, and Integrative Therapies
Background: Functional dizziness and persistent postural-perceptual dizziness (PPPD) involve mutually reinforcing vestibular symptoms and anxiety. Non-pharmacological interventions, such as vestibular rehabilitation therapy (VRT) and cognitive behavioral therapy (CBT), aim to address both mechanisms, yet their overall effectiveness remains unclear. Methods: We systematically examined randomized controlled trials (RCTs) published between 2000 and 2025 that evaluated VRT, CBT, or multimodal approaches for adults with functional or chronic dizziness (including PPPD and related functional dizziness constructs) accompanied by significant anxiety. Twelve RCTs (513 participants) met the criteria, involving individuals with PPPD, chronic subjective dizziness, chronic vestibular disorders with prominent anxiety, and residual dizziness after benign paroxysmal positional vertigo. Results: Conventional VRT delivered in clinic or as structured home-based programs produced small-to-moderate improvements in dizziness-related disability versus usual care. Combining VRT with CBT or psychologically informed components yielded larger and more consistent reductions in disability and maladaptive dizziness-related beliefs. CBT-based interventions reduced anxiety and dizziness-related distress compared with supportive controls. Emerging modalities, including virtual-reality-based VRT, non-invasive neuromodulation, and heart-rate-variability biofeedback, showed potential, although they were limited by small samples and methodological issues. Most trials had some risk-of-bias concerns and evidence certainty ranged from very low to moderate. Conclusions: Integrated multimodal rehabilitation shows promise, although larger, high-quality RCTs using standardized procedures and outcome measures are required.
- Open Access
- 5 January 2026
- Published by MDPI AG in Preprints.org
Transcranial Magnetic Stimulation in Parkinson’s Disease and Parkinsonian Syndromes: A “State-of-Art” Perspective
Transcranial magnetic stimulation (TMS) is a widely used non-invasive brain stimulation techniques that gained growing interest as a diagnostic and therapeutic tool for Parkinson’s disease (PD), as well as for some atypical parkinsonisms and secondary parkinsonian syndromes. Briefly, TMS enables targeted stimulation of specific cortical regions through externally applied magnetic pulses, avoiding surgical intervention (as occurs in deep brain stimulation) and making it a safe, repeatable, and well-tolerated approach. Over the past two decades, extensive research has explored the clinical utility of TMS in PD, with particular emphasis on motor cortex excitability, synaptic plasticity, and functional connectivity, which are central contributors to both motor and non-motor symptoms in PD patients. In addition, TMS has been shown to modulate cortical plasticity, i.e., the brain’s capacity to reorganize neural circuits, suggesting potential benefits for longer-term non-pharmacological management and rehabilitation protocols. More recently, studies have also investigated the role of TMS in atypical and secondary parkinsonisms, indicating that it may help characterize distinct neurophysiological abnormalities and provide symptomatic improvement in selected patients. This updated literature review critically synthesizes current evidence on the application of different TMS protocols across the spectrum of parkinsonian disorders, highlighting clinical potential, methodological limitations, and future research directions.
- 5 January 2026
- Published by MDPI AG in Preprints.org
Open AccessTranscranial Magnetic Stimulation in Parkinson’s Disease and Parkinsonian Syndromes: A “State-of-Art” Perspective
Transcranial magnetic stimulation (TMS) is a widely used non-invasive brain stimulation techniques that gained growing interest as a diagnostic and therapeutic tool for Parkinson’s disease (PD), as well as for some atypical parkinsonisms and secondary parkinsonian syndromes. Briefly, TMS enables targeted stimulation of specific cortical regions through externally applied magnetic pulses, avoiding surgical intervention (as occurs in deep brain stimulation) and making it a safe, repeatable, and well-tolerated approach. Over the past two decades, extensive research has explored the clinical utility of TMS in PD, with particular emphasis on motor cortex excitability, synaptic plasticity, and functional connectivity, which are central contributors to both motor and non-motor symptoms in PD patients. In addition, TMS has been shown to modulate cortical plasticity, i.e., the brain’s capacity to reorganize neural circuits, suggesting potential benefits for longer-term non-pharmacological management and rehabilitation protocols. More recently, studies have also investigated the role of TMS in atypical and secondary parkinsonisms, indicating that it may help characterize distinct neurophysiological abnormalities and provide symptomatic improvement in selected patients. This updated literature review critically synthesizes current evidence on the application of different TMS protocols across the spectrum of parkinsonian disorders, highlighting clinical potential, methodological limitations, and future research directions.
- Open Access
- 30 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Transcranial doppler detected right-to-left shunt is common but not associated with MRI white matter hyperintensity burden: a cross-sectional study
Introduction: Right-to-left shunt (RLS) associated with a patent foramen ovale has been related with ischemic stroke. However, its relationship with MRI white matter hyperintensities (WMHs) remains debated. This cross-sectional, single-centre study investigated the prevalence of RLS detected by transcranial Doppler sonography (TCD) and its association with vascular lesions on MRI. Patients and methods: 502 outpatients (mean age 47.8 ± 13 years; 45% male) with non-specific neurological symptoms underwent brain MRI and TCD with contrast saline. WMH severity was visually graded using the Fazekas scale. Results: RLS was detected in 39% of the sample. No difference was found in demographics and clinical variables between those with and without RLS. No association was also found between RLS and MRI lesion load. As expected, a significant (P < .001) positive correlation was identified between age and Fazekas scores (ie, higher scores with increasing age). No effect on lesion load was found for sex, hypercholesterolemia, diabetes, obesity and smoking, while a statistically significant association (P = .016) was present for arterial hypertension (odds ratio 1.68, 95% CI, 1.10–2.56; among those with higher Fazekas scores). Finally, no significant association was found between RLS magnitude, both at rest and during the Valsalva manoeuver and the Fazekas scores. Discussion: Although RLS was frequently detected in this cohort, it was not associated with the presence or severity of WMHs, which were instead driven by age and arterial hypertension. These findings support WMHs as MRI marker of cerebral small vessel disease rather than subclinical paradoxical embolism. This also suggests limited utility of routine TCD screening for RLS in patients with incidental WMHs and no history or sign of embolic features. Conclusions: In patients with non-specific neurological symptoms, we detected a high occurrence of RLS, although this was not associated with an increased risk or severity of WMHs. As such, paradoxical embolism may not be a major determinant of subclinical WMHs in this population.
- 30 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Open AccessTranscranial doppler detected right-to-left shunt is common but not associated with MRI white matter hyperintensity burden: a cross-sectional study
Introduction: Right-to-left shunt (RLS) associated with a patent foramen ovale has been related with ischemic stroke. However, its relationship with MRI white matter hyperintensities (WMHs) remains debated. This cross-sectional, single-centre study investigated the prevalence of RLS detected by transcranial Doppler sonography (TCD) and its association with vascular lesions on MRI. Patients and methods: 502 outpatients (mean age 47.8 ± 13 years; 45% male) with non-specific neurological symptoms underwent brain MRI and TCD with contrast saline. WMH severity was visually graded using the Fazekas scale. Results: RLS was detected in 39% of the sample. No difference was found in demographics and clinical variables between those with and without RLS. No association was also found between RLS and MRI lesion load. As expected, a significant (P < .001) positive correlation was identified between age and Fazekas scores (ie, higher scores with increasing age). No effect on lesion load was found for sex, hypercholesterolemia, diabetes, obesity and smoking, while a statistically significant association (P = .016) was present for arterial hypertension (odds ratio 1.68, 95% CI, 1.10–2.56; among those with higher Fazekas scores). Finally, no significant association was found between RLS magnitude, both at rest and during the Valsalva manoeuver and the Fazekas scores. Discussion: Although RLS was frequently detected in this cohort, it was not associated with the presence or severity of WMHs, which were instead driven by age and arterial hypertension. These findings support WMHs as MRI marker of cerebral small vessel disease rather than subclinical paradoxical embolism. This also suggests limited utility of routine TCD screening for RLS in patients with incidental WMHs and no history or sign of embolic features. Conclusions: In patients with non-specific neurological symptoms, we detected a high occurrence of RLS, although this was not associated with an increased risk or severity of WMHs. As such, paradoxical embolism may not be a major determinant of subclinical WMHs in this population.
- Open Access
- 20 November 2025
- Published by Elsevier in Pattern Recognition Letters
- Vol. 199, 205-211
SAM-guided prompt learning for Multiple Sclerosis lesion segmentation
- 20 November 2025
- Published by Elsevier in Pattern Recognition Letters
- Vol. 199, 205-211
Open AccessSAM-guided prompt learning for Multiple Sclerosis lesion segmentation
- Open Access
- 2 October 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 8 (5) , 117
Antidepressant and Related Neurobiological and Neurophysiological Effects of Add-On Transcranial Direct Current Stimulation in Major Depressive Disorder with Residual Symptoms: A Randomized, Double-Blind Clinical Trial Protocol
Major depressive disorder (MDD) is a prevalent and disabling condition. Transcranial direct current stimulation (tDCS) may improve symptoms by modulating neuroplastic and inflammatory mechanisms. This randomized, double-blind, placebo-controlled trial will recruit adult outpatients with MDD showing residual symptoms despite at least four weeks of stable SSRI treatment. Participants will be randomized to active or sham add-on tDCS while continuing their antidepressant regimen. The intervention will consist of 15 sessions over 3 weeks, targeting the left dorsolateral prefrontal cortex (anode F3, cathode F4) at 2 mA for 30 min per session. The primary outcome is the reduction of depressive symptoms measured by the Hamilton Depression Rating Scale-17 (HDRS), with remission defined as HDRS-17 ≤ 7. Secondary outcomes include cognitive performance (attention, executive functioning, memory), serum biomarkers (BDNF, VEGF, NGF, NRG1, angiogenin, IGF1, IL-6, TNF-α), cortical excitability assessed by transcranial magnetic stimulation (motor threshold, silent period, intracortical inhibition/facilitation), and cerebral hemodynamics by transcranial Doppler sonography (blood flow velocity, pulsatility, resistivity). Assessments will occur at baseline, post-treatment, and 3- and 6-month follow-ups. This trial aims to evaluate the efficacy of adjunctive tDCS in MDD with residual symptoms and its biological correlates, bridging clinical improvement with electrophysiological and neurovascular mechanisms.
- 2 October 2025
- Published by MDPI AG in Methods and Protocols
- Vol. 8 (5) , 117
Open AccessAntidepressant and Related Neurobiological and Neurophysiological Effects of Add-On Transcranial Direct Current Stimulation in Major Depressive Disorder with Residual Symptoms: A Randomized, Double-Blind Clinical Trial Protocol
Major depressive disorder (MDD) is a prevalent and disabling condition. Transcranial direct current stimulation (tDCS) may improve symptoms by modulating neuroplastic and inflammatory mechanisms. This randomized, double-blind, placebo-controlled trial will recruit adult outpatients with MDD showing residual symptoms despite at least four weeks of stable SSRI treatment. Participants will be randomized to active or sham add-on tDCS while continuing their antidepressant regimen. The intervention will consist of 15 sessions over 3 weeks, targeting the left dorsolateral prefrontal cortex (anode F3, cathode F4) at 2 mA for 30 min per session. The primary outcome is the reduction of depressive symptoms measured by the Hamilton Depression Rating Scale-17 (HDRS), with remission defined as HDRS-17 ≤ 7. Secondary outcomes include cognitive performance (attention, executive functioning, memory), serum biomarkers (BDNF, VEGF, NGF, NRG1, angiogenin, IGF1, IL-6, TNF-α), cortical excitability assessed by transcranial magnetic stimulation (motor threshold, silent period, intracortical inhibition/facilitation), and cerebral hemodynamics by transcranial Doppler sonography (blood flow velocity, pulsatility, resistivity). Assessments will occur at baseline, post-treatment, and 3- and 6-month follow-ups. This trial aims to evaluate the efficacy of adjunctive tDCS in MDD with residual symptoms and its biological correlates, bridging clinical improvement with electrophysiological and neurovascular mechanisms.
- 2 August 2024
- Published by Springer Nature
- Vol. 1458, 1-18
COVID‐19 and Mental Health: A “Pandemic Within a Pandemic”
The COVID-19 pandemic has brought significant changes in daily life for humanity and has had a profound impact on mental health. As widely acknowledged, the pandemic has led to notable increases in rates of anxiety, depression, distress, and other mental health-related issues, affecting both infected patients and non-infected individuals. COVID-19 patients and survivors face heightened risks for various neurological and psychiatric disorders and complications. Vulnerable populations, including those with pre-existing mental health conditions and individuals living in poverty or frailty, may encounter additional challenges. Tragically, suicide rates have also risen, particularly among young people, due to factors such as unemployment, financial crises, domestic violence, substance abuse, and social isolation. Efforts are underway to address these mental health issues, with healthcare professionals urged to regularly screen both COVID-19 and post-COVID-19 patients and survivors for psychological distress, ensuring rapid and appropriate interventions. Ongoing periodic follow-up and multidimensional, interdisciplinary approaches are essential for individuals experiencing long-term psychiatric sequelae. Preventive strategies must be developed to mitigate mental health problems during both the acute and recovery phases of COVID-19 infection. Vaccination efforts continue to prioritize vulnerable populations, including those with mental health conditions, to prevent future complications. Given the profound implications of mental health problems, including shorter life expectancy, diminished quality of life, heightened distress among caregivers, and substantial economic burden, it is imperative that political and health authorities prioritize the mental well-being of all individuals affected by COVID-19, including infected individuals, non-infected individuals, survivors, and caregivers.
- 2 August 2024
- Published by Springer Nature
- Vol. 1458, 1-18
COVID‐19 and Mental Health: A “Pandemic Within a Pandemic”
The COVID-19 pandemic has brought significant changes in daily life for humanity and has had a profound impact on mental health. As widely acknowledged, the pandemic has led to notable increases in rates of anxiety, depression, distress, and other mental health-related issues, affecting both infected patients and non-infected individuals. COVID-19 patients and survivors face heightened risks for various neurological and psychiatric disorders and complications. Vulnerable populations, including those with pre-existing mental health conditions and individuals living in poverty or frailty, may encounter additional challenges. Tragically, suicide rates have also risen, particularly among young people, due to factors such as unemployment, financial crises, domestic violence, substance abuse, and social isolation. Efforts are underway to address these mental health issues, with healthcare professionals urged to regularly screen both COVID-19 and post-COVID-19 patients and survivors for psychological distress, ensuring rapid and appropriate interventions. Ongoing periodic follow-up and multidimensional, interdisciplinary approaches are essential for individuals experiencing long-term psychiatric sequelae. Preventive strategies must be developed to mitigate mental health problems during both the acute and recovery phases of COVID-19 infection. Vaccination efforts continue to prioritize vulnerable populations, including those with mental health conditions, to prevent future complications. Given the profound implications of mental health problems, including shorter life expectancy, diminished quality of life, heightened distress among caregivers, and substantial economic burden, it is imperative that political and health authorities prioritize the mental well-being of all individuals affected by COVID-19, including infected individuals, non-infected individuals, survivors, and caregivers.